Skip to main content


ATS 2019

medwireNews was at the ATS 2019 International Conference in Dallas, Texas, USA, bringing you
expert interviews.

Expert interviews

22-05-2019 | Respiratory | Video

ATS 2019: Support for inhaled NO use in patients with ILD

Steven Nathan reports the results of an 8-week randomised placebo-controlled trial in which inhaled nitric oxide was associated with an increase in actigraphy-measured physical activity among interstitial lung disease patients at risk of pulmonary hypertension (5:12).

22-05-2019 | Respiratory | Video

ATS 2019: New vessel-analysis tool predicts IPF outcome

Joseph Jacob outlines evidence supporting the use of a new tool measuring vessel parameters on computed tomography scans to predict mortality risk in patients with idiopathic pulmonary fibrosis (5:24).

21-05-2019 | Respiratory | Video

ATS 2019: Aspergillus infection linked to CF lung disease progression

Oded Breuer outlines a longitudinal study in which infection with Aspergillus species was shown to be associated with worse current structural lung disease and more rapid progression among young children with cystic fibrosis (3:38).

21-05-2019 | Respiratory | Video

ATS 2019: Pathophysiological features occur at very early stages of IPF

Feng Xu summarises research showing that the pathophysiological features of idiopathic pulmonary fibrosis are present before the time that symptoms usually appear, which could represent a window of opportunity to prevent disease progression (4:42).

21-05-2019 | Respiratory | Video

ATS 2019: CFTR modulators impact immune cell function in cystic fibrosis

Benjamin Kopp discusses study findings demonstrating that CFTR modulator therapies have a differential impact on immune cell function depending on the agent used and the patient’s genotype, which has implications for clearing chronic airway infections in individuals with cystic fibrosis (3:25).

20-05-2019 | Asthma | Video

ATS 2019: Exhaled VOCs discriminate between eosinophilic and neutrophilic asthma

Florence Schleich presents study results showing that exhaled volatile organic compounds may be able to distinguish eosinophilic asthma from the neutrophilic subtype (2:04).

20-05-2019 | Chronic obstructive pulmonary disease | Video

ATS 2019: No reduction in COPD exacerbation rate with benralizumab treatment

Gerard Criner reports findings from the placebo-controlled GALATHEA and TERRANOVA trials, demonstrating that add-on benralizumab does not reduce exacerbation rates among patients with moderate to very severe chronic obstructive pulmonary disease (3:27).

20-05-2019 | Asthma | Video

ATS 2019: Many patients with mild asthma have low eosinophil levels

Stephen Lazarus outlines findings from the SIENA crossover trial, in which almost three-quarters of patients with mild, persistent asthma were shown to have sputum eosinophil levels below 2%, and the majority of participants did not have a significantly better response to mometasone or tiotropium versus placebo (5:16).

23-05-2019 | Chronic obstructive pulmonary disease | Video

ATS 2019: Eosinophil-guided strategy reduces corticosteroid use in hospitalised COPD patients

Pradeesh Sivapalan and Jens-Ulrik Jensen talk us through CORTICO-COP, a randomised trial indicating that eosinophil-guided therapy is noninferior to standard care for the treatment of acute chronic obstructive pulmonary disease exacerbations, and reduces the duration of corticosteroid exposure (6:47).

18-09-2019 | Oncology | News | Article

Nivolumab confers NSCLC survival advantage over 5 years

Individuals with advanced non-small-cell lung cancer continue to derive a long-term survival benefit from second- or later-line treatment with nivolumab versus docetaxel, according to 5-year results from the CheckMate 017 and 057 trials.

16-09-2019 | Oncology | News | Article

Special NSCLC populations can benefit from nivolumab plus ipilimumab

Non-small-cell lung cancer patients with poor performance status or comorbidity experience a similar adverse event rate to those with normal performance status when treated with nivolumab plus ipilimumab, say researchers.

13-09-2019 | Oncology | News | Article

IMpower131: Strongly PD-L1-positive NSCLC patients may benefit from atezolizumab–chemotherapy

The final analysis of the IMpower131 trial reveals an overall survival benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous non-small-cell lung cancer who strongly express PD-L1.

12-09-2019 | Oncology | News | Article

LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC

Selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced non-small-cell lung cancer harboring RET fusions, show updated trial data presented at the IASLC World Conference on Lung Cancer 2019.

Twitter Icon Follow medwireNews

Click here
Image Credits